<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37170730</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-185X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>International journal of rheumatic diseases</Title><ISOAbbreviation>Int J Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Study of 43 SLE patients with autoimmune liver cirrhosis: emphasis on clinical features and differences from lupus without cirrhosis.</ArticleTitle><Pagination><StartPage>1268</StartPage><EndPage>1275</EndPage><MedlinePgn>1268-1275</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1756-185X.14712</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the clinical characteristics of systemic lupus erythematosus accompanied by autoimmune liver cirrhosis (SLE-ALC) patients and differences from the non-cirrhosis group.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty-three patients with SLE-ALC were enrolled in this study from 2653 patients with SLE in Peking University People's Hospital. A descriptive case-control study was performed between SLE-ALC patients and the entry time-matched non-cirrhosis group.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 43 SLE-ALC patients, 41 (95.3%) were female. Eight patients (18.6%) were first found to have cirrhosis and then diagnosed with SLE. Eighteen patients (41.9%) had jaundice and 27 (62.8%) had esophageal and gastric varices. The age of SLE-ALC patients was 51.1&#x2009;&#xb1;&#x2009;17.2&#x2009;years, which was significantly older than the non-cirrhosis group (P&#x2009;&lt;&#x2009;0.001). Lung involvement was more common as initial manifestations in SLE-ALC patients during the SLE course (P=0.027). Compared with the non-cirrhosis group, SLE-ALC patients had worse liver function. A significantly higher rate of hematological system involvement (anemia, leucopenia, and thrombocytopenia) and a higher level of immunoglobulins were observed in SLE-ALC patients (P&lt;0.05). Moreover, SLE-ALC patients displayed a lower positive rate of anti-double-stranded DNA and anti-ribosomal P protein (P&lt;0.05). The most common radiologic manifestations are ascitic fluid (72.1%) and splenomegaly (71.4%) in SLE-ALC patients. Six SLE-ALC patients underwent liver biopsy, and interface hepatitis was present in all patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cirrhosis is rare in SLE patients but is manifested as a unique pattern of clinical features characterized by late-onset age, lung involvement, high immunoglobulins, and impaired liver function.</AbstractText><CopyrightInformation>&#xa9; 2023 Asia Pacific League of Associations for Rheumatology and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiao-Ying</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Second Hospital of Shanxi Medical University, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yu-Xin</ForeName><Initials>YX</Initials><Identifier Source="ORCID">0000-0003-0794-7646</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zi-Qiao</ForeName><Initials>ZQ</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xin-Yu</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Department of Radiology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Jia-Yang</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Yu-Zhou</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan-Min</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Second Department of liver disease center, Beijing Youan Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan-Ying</ForeName><Initials>YY</Initials><Identifier Source="ORCID">0000-0003-2609-4052</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhan-Guo</ForeName><Initials>ZG</Initials><Identifier Source="ORCID">0000-0002-2590-6242</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022-2-2026</GrantID><Agency>Capital's Funds for Health Improvement and Research</Agency><Country/></Grant><Grant><GrantID>U1903210</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Rheum Dis</MedlineTA><NlmUniqueID>101474930</NlmUniqueID><ISSNLinking>1756-1841</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008107" MajorTopicYN="Y">Liver Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmune hepatitis</Keyword><Keyword MajorTopicYN="N">liver cirrhosis</Keyword><Keyword MajorTopicYN="N">primary biliary cholangitis</Keyword><Keyword MajorTopicYN="N">primary sclerosing cholangitis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37170730</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.14712</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Gebreselassie A, Aduli F, Howell CD. Rheumatologic diseases and the liver. Clin Liver Dis. 2019;23:247-261.</Citation></Reference><Reference><Citation>Piga M, Vacca A, Porru G, Cauli A, Mathieu A. Liver involvement in systemic lupus erythematosus: incidence, clinical course and outcome of lupus hepatitis. Clin Exp Rheumatol. 2010;28:504-510.</Citation></Reference><Reference><Citation>Zheng RH, Wang JH, Wang SB, Chen J, Guan WM, Chen MH. Clinical and immunopathological features of patients with lupus hepatitis. Chin Med J. 2013;126:260-266.</Citation></Reference><Reference><Citation>Ebert EC, Hagspiel KD. Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol. 2011;45:436-441.</Citation></Reference><Reference><Citation>Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis. 2004;63:123-129.</Citation></Reference><Reference><Citation>Bessone F, Poles N, Roma MG. Challenge of liver disease in systemic lupus erythematosus: clues for diagnosis and hints for pathogenesis. World J Hepatol. 2014;6:394-409.</Citation></Reference><Reference><Citation>Beisel C, Weiler-Normann C, Teufel A, Lohse AW. Association of autoimmune hepatitis and systemic lupus erythematodes: a case series and review of the literature. World J Gastroenterol. 2014;20:12662-12667.</Citation></Reference><Reference><Citation>Sandhu V, Jawad AS. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis. 2004;63:1004-1005; discussion 5.</Citation></Reference><Reference><Citation>Matsumoto T, Yoshimine T, Shimouchi K, et al. The liver in systemic lupus erythematosus: pathologic analysis of 52 cases and review of Japanese autopsy registry data. Hum Pathol. 1992;23:1151-1158.</Citation></Reference><Reference><Citation>Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med. 1980;69:187-194.</Citation></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.</Citation></Reference><Reference><Citation>Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749-1761.</Citation></Reference><Reference><Citation>Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169-176.</Citation></Reference><Reference><Citation>Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009;50:291-308.</Citation></Reference><Reference><Citation>Matsumoto T, Kobayashi S, Shimizu H, et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver. 2000;20:366-373.</Citation></Reference><Reference><Citation>Ahmad A, Heijke R, Eriksson P, et al. Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes. Clin Exp Immunol. 2021;203:22-31.</Citation></Reference><Reference><Citation>Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet. 1959;1:65-69.</Citation></Reference><Reference><Citation>Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Lanzoni VP, Ferraz ML, Silva AE. Late-onset systemic lupus erythematosus-associated liver disease. Rheumatol Int. 2012;32:2917-2920.</Citation></Reference><Reference><Citation>Keeling DM, Isenberg DA. Haematological manifestations of systemic lupus erythematosus. Blood Rev. 1993;7:199-207.</Citation></Reference><Reference><Citation>Lim DH, Kim YG, Lee D, et al. Immunoglobulin G levels as a prognostic factor for autoimmune hepatitis combined with systemic lupus erythematosus. Arthritis Care Res. 2016;68:995-1002.</Citation></Reference><Reference><Citation>Takahashi A, Abe K, Saito R, et al. Liver dysfunction in patients with systemic lupus erythematosus. Intern Med. 2013;52:1461-1465.</Citation></Reference><Reference><Citation>Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338-347.</Citation></Reference><Reference><Citation>Briani C, Lucchetta M, Ghirardello A, et al. Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. J Autoimmun. 2009;32:79-84.</Citation></Reference><Reference><Citation>Shizuma T, Kuroda H. A case of primary biliary cirrhosis which developed eight years after diagnosis of systemic lupus erythematosus. Intern Med. 2011;50:321-324.</Citation></Reference><Reference><Citation>Deen ME, Porta G, Fiorot FJ, Campos LM, Sallum AM, Silva CA. Autoimmune hepatitis and juvenile systemic lupus erythematosus. Lupus. 2009;18:747-751.</Citation></Reference><Reference><Citation>Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG. Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol. 2008;35:2159-2164.</Citation></Reference><Reference><Citation>Shizuma T. Clinical characteristics of concomitant systemic lupus erythematosus and primary biliary cirrhosis: a literature review. J Immunol Res. 2015;2015:713728.</Citation></Reference><Reference><Citation>Onder FO, Y&#xfc;rekli OT, Ozta&#x15f; E, et al. Features of systemic lupus erythematosus in patients with autoimmune hepatitis. Rheumatol Int. 2013;33:1581-1585.</Citation></Reference><Reference><Citation>Grover S, Rastogi A, Singh J, Rajbongshi A, Bihari C. Spectrum of Histomorphologic findings in liver in patients with SLE: a review. Hepat Res Treat. 2014;2014:562979.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>